Durgical
EN
Open the app

Lurasidone

  • Second-generation antipsychoticsSecond-generation antipsychotics

A second-generation antipsychotic for schizophrenia and bipolar depression. It must be taken with a meal and cannot be combined with strong CYP3A4 drugs.

Updated

Quick facts

Group
Second-generation antipsychotics
Target
Dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors
Used for
Schizophrenia in adults and adolescents
Key effects
Akathisia · Sleepiness · Nausea
Monitor
Weight · Akathisia and other movement disorders
ATC
N05AE05

No doses: the clinician sets them by the current guideline.

Mechanism of action

The figure shows risperidone in the human D2 receptor; lurasidone blocks the same receptor site (no lurasidone-bound structure is available).

Target in 3D: Dopamine D2 and serotonin 5-HT2A and 5-HT7 receptors. PDB structure 6CM4 (RCSB PDB, public domain). View the structure at RCSB PDB

Lurasidone blocks dopamine D2 and serotonin 5-HT2A receptors, the shared action of second-generation antipsychotics, and also blocks 5-HT7 receptors. 5-HT7 antagonism is one proposed explanation for its antidepressant effect in bipolar depression. Akathisia is a common adverse effect.

  1. Blocks D2 and 5-HT2A receptors
  2. Also blocks 5-HT7 receptors
  3. Treats psychosis and bipolar depression
  4. Common motor effect: akathisia

Indications

Adverse effects

Common

  • Akathisia (restlessness) and other extrapyramidal symptoms
  • Sleepiness
  • Nausea
  • Raised prolactin: breast changes, missed periods

Contraindications

  • Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir)
  • Strong CYP3A4 inducers (rifampicin, St John's wort, phenytoin, carbamazepine)
  • Hypersensitivity to lurasidone

Key interactions

Strong CYP3A4 inhibitors
Large rise in lurasidone levels and toxicity; contraindicated.
Strong CYP3A4 inducers
Levels fall so much that it stops working; contraindicated.
Grapefruit juice
Large amounts can raise levels; avoided.

What is monitored

  • Weight, glucose and lipids
  • Akathisia and other movement disorders
  • Mood and suicidal thoughts in bipolar depression
  • Liver and kidney function (doses are lower in impairment)

Administration and safety

  • Oral tablet once a day with a meal (a real meal, not a snack).
  • Every new prescription is checked for strong CYP3A4 inhibitors or inducers before starting.
  • The dose is lowered in moderate or severe liver or kidney impairment.

Pregnancy and breastfeeding

Newborns exposed in the third trimester may have extrapyramidal or withdrawal symptoms; use weighs benefit and risk.

Nursing care

  • Before: record weight, glucose and lipids; review all medicines and herbal products.
  • During: ask about restlessness and inability to sit still; report it.
  • Watch mood and suicidal thoughts.
  • Teach to take it with food and to avoid grapefruit and alcohol.

Pharmacokinetics

Absorption
Oral; food greatly increases absorption, so it is taken with a meal.
Metabolism
Liver, by CYP3A4.

Test yourself

Think of the answer, then tap the question to see it.

Why must lurasidone be taken with food?

Food greatly increases its absorption; on an empty stomach levels are too low.

Why are rifampicin and ketoconazole contraindicated with lurasidone?

Lurasidone depends on CYP3A4: the inducer makes it ineffective and the inhibitor makes it toxic.

Which movement side effect is especially common with lurasidone?

Akathisia (inner restlessness).

Add to my cards (3)

More Pharmacology questions →

Connections

← Back to the class: Second-generation antipsychotics

Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given.

Sources: Lurasidone: MedlinePlus Drug Information (MedlinePlus (U.S. National Library of Medicine), 2025); LURASIDONE HYDROCHLORIDE tablet, film coated (DailyMed (U.S. National Library of Medicine), 2026); Structure of the D2 Dopamine Receptor Bound to the Atypical Antipsychotic Drug Risperidone (RCSB Protein Data Bank, 2018); ATCDDD - ATC/DDD Index (WHO Collaborating Centre for Drug Statistics Methodology, 2026).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.